Cardiac Water and Fluoromethane Cardiac PET

• Sponsor: University of Wisconsin, Madison (Other)
• Overall Status: Completed
• CT.gov ID: NCT00205127
• Collaborator: (none)
• Enrollment: 10
• Location: 1
• Duration (Months): 2
• Patients Per Site Per Month: 5.1

Study Details

Study Description

Brief Summary

In this study we are looking at the blood flow to the heart using two different chemical tags or tracers that give off a low level of radiation. The tracers used in this study are called O15-water and F17-fluoromethane. These tracers mix with the blood and will move through the body. The researchers will use positron emission tomography (PET scans)to track the tracers as they moe through the heart and chest.

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteers	Procedure: Cardiac PET imaging- rest and pharmacological stress	N/A

Study Design

• Study Type: Interventional
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Comparison of Cardiac Perfusion by O15-water and F17-fluoromethane PET
• Study Start Date: Jan 1, 2004
• Actual Primary Completion Date: Mar 1, 2004
• Actual Study Completion Date: Mar 1, 2004

Outcome Measures

Primary Outcome Measures

1. -- implement myocardial perfusion quantification for O15-labeled water at rest and with pharmacologic stress, [assess at time of PET scan]

2. -- determine the biodistribution of fluoromethane in the thorax to see if it is usable for a cardiac perfusion tracer, [assess at time of PET Scan]

Secondary Outcome Measures

1. --develop initial methods for quantification of myocardial perfusion if applicable for labeled fluoromethane. [assess at time of PET scan]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 40 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• 1. Age 18 to 40 years old 2. Willing to provide written informed consent

Exclusion Criteria:

• 1. A history of CAD 2. A history of active bronchospasm or asthma on theophylline bronchodilators 3. A history of any cardiac risk factors including: HTN, Diabetes, Hyperlipidemia, Smoking, and premature CAD in immediate family member 4. A history of liver disease or other significant disease 5. Females who are pregnant or lactating

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Wisconsin	Madison	Wisconsin	United States	53792

Sponsors and Collaborators

• University of Wisconsin, Madison

Investigators

• Principal Investigator: Charles K Stone, MD, Univeristy of Wisconsin

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University of Wisconsin, Madison
• ClinicalTrials.gov Identifier: NCT00205127
• Other Study ID Numbers: 2003-241
• First Posted: Sep 20, 2005
• Last Update Posted: Aug 29, 2012
• Last Verified: Aug 1, 2012

• Keywords provided by University of Wisconsin, Madison: Cardiac PET imaging; Radiopharmaceutical tracers

Study Results

No Results Posted as of Aug 29, 2012